HKSE 2228.HK XtalPi Holdings Ltd at HK$11.28 intraday 07 Feb 2026: AI drug discovery outlook

At HK$11.28 intraday on 07 Feb 2026, 2228.HK stock trades with a day range of HK$11.09–HK$11.61 and volume at 38,239,234.00 shares. Investors watch XtalPi Holdings Ltd (2228.HK) on the Hong Kong Stock Exchange for AI-driven drug discovery progress. The stock shows a trailing EPS of HK$1.05 and a reported PE of 10.74, while 50-day and 200-day averages sit at HK$10.89 and HK$8.87 respectively. This intraday snapshot frames technical momentum, valuation tensions, and modelling-led forecasts

Intraday snapshot and market context

2228.HK stock quotes HK$11.28 on the HKSE in Hong Kong with market cap HKD 48,542,033,464.00. The session opened at HK$11.14 and previous close was HK$11.28. Year range is HK$3.85–HK$15.12, average daily volume is 74,321,788.00, and today’s volume is 38,239,234.00. The Healthcare sector in Hong Kong has lagged some tech peers, but AI-enabled drug discovery remains a growth theme that affects XtalPi’s flows

2228.HK stock technicals & momentum

Momentum is strong and short-term indicators show overbought conditions. RSI is 76.82, Stochastic %K/%D near 95.96/95.28, and MACD histogram at 0.35. Bollinger upper band sits at HK$11.80 with middle at HK$9.99. ATR is HK$0.52, so intraday moves of about HK$0.50 are typical. Traders seeing RSI above 70 may expect short-term pullbacks toward the 50-day average at HK$10.89

Fundamentals and valuation for XtalPi Holdings Ltd (2228.HK)

Fundamentals show mixed signals for 2228.HK stock. Reported EPS is HK$1.05 and reported PE is 10.74, but key ratios highlight heavy growth investment. Price to sales is 63.28, price to book is 5.39, and current ratio is 9.69, reflecting a strong liquidity buffer. R&D to revenue is 63.06%, which supports the AI drug discovery thesis but depresses margins

Meyka AI rates 2228.HK with a score out of 100

Meyka AI rates 2228.HK with a score out of 100: 63.15 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Company-level ratings show a contrasting view; a dated company rating flagged C- (Strong Sell) on 06 Feb 2026, reflecting valuation and margin concerns. Meyka AI’s forecast model projects monthly HK$14.10, quarterly HK$13.43, and yearly HK$10.47. Compared with the current price of HK$11.28, the model implies a near-term upside of 25.00% to the monthly target, 19.06% to the quarterly target, and a -7.18% change to the 12-month projection. Forecasts are model-based projections and not guarantees

Risks and opportunities for AI-focused investors

Opportunity: XtalPi’s AI and automation platforms target small molecules, antibodies and PROTACs and can win long-term pharma contracts if algorithms scale. Risk: long receivables at 268.35 days and persistent negative operating cash flow per share at -HK$0.11 signal execution and monetisation pressures. Valuation is high on sales, while liquidity and low debt offer a runway. Regulatory or pharma-partner delays would compress upside

Trading strategy and analyst-style price targets

From a market-analysis view, near-term resistance is HK$11.80 and support sits near HK$11.00 and the 50-day average HK$10.89. A sensible scenario framing: tactical target HK$13.50 (near-term) and 12-month model target HK$10.47 from Meyka AI’s forecast. Use technical confirmation before increasing exposure and watch earnings on 2026-03-27 for revenue and margin updates. For institutional flows, note the relatively large outstanding shares at 4,303,371,761.00

Final Thoughts

Key takeaways on 2228.HK stock: intraday price is HK$11.28 with solid liquidity and strong short-term momentum, but indicators show overbought conditions that can invite a pullback to the 50-day average HK$10.89. Valuation mixes a modest reported PE of 10.74 with elevated price-to-sales and price-to-book ratios. Meyka AI’s forecast model projects monthly HK$14.10, quarterly HK$13.43, and yearly HK$10.47, implying a near-term upside of 25.00% and a 12-month downside of -7.18% versus the current price. Meyka AI, our AI-powered market analysis platform, assigns a 63.15 score (Grade B, HOLD) balancing growth potential and execution risk. Investors focusing on the AI drug discovery theme should weigh contract wins and R&D cadence against stretched sales multiples and operational metrics like days sales outstanding. Forecasts are model-based projections and not guarantees

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.